Satavaptan (sr121463b)    (DrugBank: Satavaptan)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
72下垂体性ADH分泌異常症6

72. 下垂体性ADH分泌異常症 [臨床試験数:36,薬物数:22(DrugBank:5),標的遺伝子数:2,標的パスウェイ数:4
Searched query = "Pituitary ADH secretion disorder", "Inappropriate antidiuretic hormone secretion", "Syndrome of inappropriate secretion of antidiuretic hormone", "Inappropriate ADH syndrome", "Syndrome of inappropriate ADH", "Central diabetes insipidus", "Syndrome of inappropriate secretion of ADH", "SIADH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 36 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-007941-10-BE
(EUCTR)
10/09/200802/07/2008A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of two doses of Satavaptan (SR121463B) Versus Placebo in Patients with Dilutional Hyponatremia due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) - AQUARIST IA Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of two doses of Satavaptan (SR121463B) Versus Placebo in Patients with Dilutional Hyponatremia due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) - AQUARIST I Dilutional hyponatraemia. MedRA term HYPONATRAEMIA
MedDRA version: 10.1;Level: LLT;Classification code 10021036;Term:
Product Name: satavaptan
Product Code: SR121463B
INN or Proposed INN: satavaptan
Product Name: satavaptan
Product Code: SR121463B
INN or Proposed INN: satavaptan
sanofi-aventis recherche et développementNULLNot RecruitingFemale: yes
Male: yes
129France;Hungary;Belgium;Germany
2EUCTR2007-007941-10-HU
(EUCTR)
04/08/200812/06/2008A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of two doses of Satavaptan (SR121463B) Versus Placebo in Patients with Dilutional Hyponatremia due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) - AQUARIST I Dilutional hyponatraemia. MedRA term HYPONATRAEMIA
MedDRA version: 9.1;Level: LLT;Classification code 10021036;Term: Hyponatraemia
Product Name: satavaptan
Product Code: SR121463B
INN or Proposed INN: satavaptan
Product Name: satavaptan
Product Code: SR121463B
INN or Proposed INN: satavaptan
sanofi-aventis recherche et développementNULLNot RecruitingFemale: yes
Male: yes
129Hungary;Germany;Belgium;France
3NCT00728091
(ClinicalTrials.gov)
July 200831/7/2008A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional HyponatremiaA Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)Hyponatremia;Inappropriate ADH SyndromeDrug: satavaptan (SR121463);Drug: placeboSanofiNULLTerminated18 YearsN/ABoth2Phase 3United States
4EUCTR2007-007941-10-FR
(EUCTR)
16/06/200815/04/2008A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of two doses of Satavaptan (SR121463B) Versus Placebo in Patients with Dilutional Hyponatremia due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) - AQUARIST I Dilutional hyponatraemia. MedRA term HYPONATRAEMIA
MedDRA version: 10.1;Level: LLT;Classification code 10021036;Term:
Product Name: satavaptan
Product Code: SR121463B
INN or Proposed INN: satavaptan
Product Name: satavaptan
Product Code: SR121463B
INN or Proposed INN: satavaptan
sanofi-aventis recherche et développementNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
129Hungary;Germany;Belgium;France
5EUCTR2007-007941-10-DE
(EUCTR)
11/06/200802/04/2008A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of two doses of Satavaptan (SR121463B) Versus Placebo in Patients with Dilutional Hyponatremia due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) - AQUARIST I Dilutional hyponatraemia. MedRA term HYPONATRAEMIA
MedDRA version: 10.1;Level: LLT;Classification code 10021036;Term:
Product Name: satavaptan
Product Code: SR121463B
INN or Proposed INN: satavaptan
Product Name: satavaptan
Product Code: SR121463B
INN or Proposed INN: satavaptan
sanofi-aventis recherche et développementNULLNot RecruitingFemale: yes
Male: yes
129Hungary;Germany;Belgium;France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00032734
(ClinicalTrials.gov)
June 200129/3/2002Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone SecretionA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion.Syndrome of Inappropriate ADH (SIADH) Secretion;HyponatremiaDrug: satavaptan (SR121463B)SanofiNULLCompleted18 YearsN/ABoth35Phase 2Belgium;France;Germany;Hungary;United States;Canada